期刊
BLOOD REVIEWS
卷 24, 期 1, 页码 39-47出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2009.09.001
关键词
Anemia; Chronic kidney disease; Erythropoietin; Erythropoiesis-stimulating agents; Ferritin; Transferrin saturation; Iron deficiency; Erythropoietin resistance
类别
Chronic kidney disease (CKD) is a widespread health problem in the world and anemia is a common complication. Anemia conveys significant risk for cardiovascular disease, faster progression of renal failure and decreased quality of life. Patients with CKD can have anemia for many reasons, including but not invariably their renal insufficiency. These patients require a thorough evaluation to identify and correct causes of anemia other than erythropoietin deficiency. The mainstay of treatment of anemia secondary to CKD has become erythropoiesis-stimulating agents (ESAs). The use of ESAs does carry risks and these agents need to be used judiciously. Iron deficiency often co-exists in this population and must be evaluated and treated. Correction of iron deficiency can improve anemia and reduce ESA requirements. Partial, but not complete, correction of anemia is associated with improved outcomes in patients with CKD. (c) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据